Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Non-Current Liabilities (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Other Non-Current Liabilities data on record, last reported at $1.8 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, changed N/A, while the annual FY2024 figure was $2.6 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $1.8 million in Q3 2025 per VRCA's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.6 million in Q4 2024 and bottomed at $5000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 3 years is $1.4 million, with a median of $1.8 million recorded in 2025.